Pluristem to Develop Stem Cell Therapy On Its Own

Israeli biotech Pluristem will advance its stem cell therapy for critical limb ischemia, a severe obstruction of arteries that can lead to amputation. The $38 million raised by a public offering will enable Pluristem to carry its placental-derived mesenchymal-like stem cell therapy all the way to a phase III trial and may help speed its eventual translation for ALS.

Click here to read more.

Share this: